MediciNova Q2 net loss $2.3 mln

By Admin
MediciNova Inc said it has reported a net loss of $2.3 million or $0.14 per share in second quarter ended June 30, 2012. The biopharmaceutical company...

MediciNova Inc said it has reported a net loss of $2.3 million or $0.14 per share in second quarter ended June 30, 2012. The biopharmaceutical company had reported a net loss of $4.7 million or $0.31 a share in the corresponding period last year.

The research and development service revenue pertaining to the Kissei services agreement was $0.5 million.

In the second quarter, MediciNova’s R&D expenses stood at $1.5 million compared to $2.0 million posted in the same quarter last year. The decline in the R&D expenses was on account of a decrease in the spending on the prioritized asset MN-221 for treating acute exacerbations of asthma and COPD. Another reason for the plunge in R&D expenses is the lower stock based compensation expense in the most recent quarter.

For the quarter ended June 30, 2012, the general and administrative expenses fell by $1.3 million due to the decrease in the stock-based compensation expense, partially offset by increase in compensation expense pertaining to the bonus of employees.

The company had $7.3 million in cash and cash equivalents as of June 30, 2012, as against $15.1 million of cash and cash equivalents at December 31, 2011.

MediciNova is a publicly traded biopharmaceutical company founded on acquisition of developing novel, small-molecule therapeutics for treating diseases with unmet needs with a commercial focus on the U.S. market.

Share

Featured Articles

Philips Future Health Index Report: AI to Cut Waiting Times

Healthcare technology leader Philips says virtual care and AI is turning in an effort to cope with demand in its Future Health Index Report 2024

HCLTech and Olympus Advance AI into the Healthcare Industry

Giants HCLTech and Olympus Corporation, have developed their partnership to utilise technology and AI to transform the healthcare industry.

Cancer Vaccines Breakthrough a Glimpse of Healthcare Future

As the UK's NHS becomes the first healthcare provider to launch a cancer vaccine testing programme, we explore this groundbreaking oncological treatment

Change Healthcare Cyberattack Fallout Continues

Health Insurance & Finance

McKinsey: National E-health Initiatives on the Rise

Technology & AI

Edwards Lifesciences: a Profile of the Heart Tech Specialist

Medical Devices & Pharma